Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 755

1.

Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.

Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR.

JCI Insight. 2017 Mar 23;2(6):e90449. doi: 10.1172/jci.insight.90449.

PMID:
28352657
2.

Functional variomics and network perturbation: connecting genotype to phenotype in cancer.

Yi S, Lin S, Li Y, Zhao W, Mills GB, Sahni N.

Nat Rev Genet. 2017 Mar 27. doi: 10.1038/nrg.2017.8. [Epub ahead of print] Review.

PMID:
28344341
3.

Integrated Molecular Characterization of Uterine Carcinosarcoma.

Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB; Cancer Genome Atlas Research Network., Weinstein JN, Zhang J, Akbani R, Levine DA.

Cancer Cell. 2017 Mar 13;31(3):411-423. doi: 10.1016/j.ccell.2017.02.010.

4.

CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.

Kurnit KC, Kim GN, Fellman BM, Urbauer DL, Mills GB, Zhang W, Broaddus RR.

Mod Pathol. 2017 Mar 10. doi: 10.1038/modpathol.2017.15. [Epub ahead of print]

PMID:
28281553
5.

YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway.

Wang C, Gu C, Jeong KJ, Zhang D, Guo W, Lu Y, Ju Z, Panupinthu N, Yang JY, Gagea MM, Ng PK, Zhang F, Mills GB.

Cancer Res. 2017 Feb 15. doi: 10.1158/0008-5472.CAN-15-3084. [Epub ahead of print]

PMID:
28202507
6.

Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.

Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H.

Cancer Cell. 2017 Feb 13;31(2):225-239. doi: 10.1016/j.ccell.2017.01.005.

PMID:
28196595
7.

Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.

Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, Rathmell WK, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS; Cancer Genome Atlas Research Network., Pacak K, Nathanson KL, Wilkerson MD.

Cancer Cell. 2017 Feb 13;31(2):181-193. doi: 10.1016/j.ccell.2017.01.001. Epub 2017 Feb 2.

PMID:
28162975
8.

Integrated genomic and molecular characterization of cervical cancer.

Cancer Genome Atlas Research Network.; Albert Einstein College of Medicine.; Analytical Biological Services.; Barretos Cancer Hospital.; Baylor College of Medicine.; Beckman Research Institute of City of Hope.; Buck Institute for Research on Aging.; Canada's Michael Smith Genome Sciences Centre.; Harvard Medical School.; Helen F. Graham Cancer Center &Research Institute at Christiana Care Health Services.; HudsonAlpha Institute for Biotechnology.; ILSbio, LLC.; Indiana University School of Medicine.; Institute of Human Virology.; Institute for Systems Biology.; International Genomics Consortium.; Leidos Biomedical.; Massachusetts General Hospital.; McDonnell Genome Institute at Washington University.; Medical College of Wisconsin.; Medical University of South Carolina.; Memorial Sloan Kettering Cancer Center.; Montefiore Medical Center.; NantOmics.; National Cancer Institute.; National Hospital, Abuja, Nigeria.; National Human Genome Research Institute.; National Institute of Environmental Health Sciences.; National Institute on Deafness &Other Communication Disorders.; Ontario Tumour Bank, London Health Sciences Centre.; Ontario Tumour Bank, Ontario Institute for Cancer Research.; Ontario Tumour Bank, The Ottawa Hospital.; Oregon Health &Science University.; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center.; SRA International.; St Joseph's Candler Health System.; Eli &Edythe L. Broad Institute of Massachusetts Institute of Technology &Harvard University.; Research Institute at Nationwide Children's Hospital.; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.; University of Bergen.; University of Texas MD Anderson Cancer Center.; University of Abuja Teaching Hospital.; University of Alabama at Birmingham.; University of California, Irvine.; University of California Santa Cruz.; University of Kansas Medical Center.; University of Lausanne.; University of New Mexico Health Sciences Center.; University of North Carolina at Chapel Hill.; University of Oklahoma Health Sciences Center.; University of Pittsburgh.; University of São Paulo, Ribeir ão Preto Medical School.; University of Southern California.; University of Washington.; University of Wisconsin School of Medicine &Public Health.; Van Andel Research Institute.; Washington University in St Louis..

Nature. 2017 Mar 16;543(7645):378-384. doi: 10.1038/nature21386. Epub 2017 Jan 23.

PMID:
28112728
9.

A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.

George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F.

JCI Insight. 2017 Jan 12;2(1):e89760. doi: 10.1172/jci.insight.89760.

10.

Integrated genomic characterization of oesophageal carcinoma.

Cancer Genome Atlas Research Network.; Analysis Working Group: Asan University.; BC Cancer Agency.; Brigham and Women’s Hospital.; Broad Institute.; Brown University.; Case Western Reserve University.; Dana-Farber Cancer Institute.; Duke University.; Greater Poland Cancer Centre.; Harvard Medical School.; Institute for Systems Biology.; KU Leuven.; Mayo Clinic.; Memorial Sloan Kettering Cancer Center.; National Cancer Institute.; Nationwide Children’s Hospital.; Stanford University.; University of Alabama.; University of Michigan.; University of North Carolina.; University of Pittsburgh.; University of Rochester.; University of Southern California.; University of Texas MD Anderson Cancer Center.; University of Washington.; Van Andel Research Institute.; Vanderbilt University.; Washington University.; Genome Sequencing Center: Broad Institute.; Washington University in St. Louis.; Genome Characterization Centers: BC Cancer Agency.; Broad Institute.; Harvard Medical School.; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.; University of North Carolina.; University of Southern California Epigenome Center.; University of Texas MD Anderson Cancer Center.; Van Andel Research Institute.; Genome Data Analysis Centers: Broad Institute.; Brown University:.; Harvard Medical School.; Institute for Systems Biology.; Memorial Sloan Kettering Cancer Center.; University of California Santa Cruz.; University of Texas MD Anderson Cancer Center.; Biospecimen Core Resource: International Genomics Consortium.; Research Institute at Nationwide Children’s Hospital.; Tissue Source Sites: Analytic Biologic Services.; Asan Medical Center.; Asterand Bioscience.; Barretos Cancer Hospital.; BioreclamationIVT.; Botkin Municipal Clinic.; Chonnam National University Medical School.; Christiana Care Health System.; Cureline.; Duke University.; Emory University.; Erasmus University.; Indiana University School of Medicine.; Institute of Oncology of Moldova.; International Genomics Consortium.; Invidumed.; Israelitisches Krankenhaus Hamburg.; Keimyung University School of Medicine.; Memorial Sloan Kettering Cancer Center.; National Cancer Center Goyang.; Ontario Tumour Bank.; Peter MacCallum Cancer Centre.; Pusan National University Medical School.; Ribeirão Preto Medical School.; St. Joseph’s Hospital &Medical Center.; St. Petersburg Academic University.; Tayside Tissue Bank.; University of Dundee.; University of Kansas Medical Center.; University of Michigan.; University of North Carolina at Chapel Hill.; University of Pittsburgh School of Medicine.; University of Texas MD Anderson Cancer Center.; Disease Working Group: Duke University.; Memorial Sloan Kettering Cancer Center.; National Cancer Institute.; University of Texas MD Anderson Cancer Center.; Yonsei University College of Medicine.; Data Coordination Center: CSRA Inc.; Project Team: National Institutes of Health..

Nature. 2017 Jan 12;541(7636):169-175. doi: 10.1038/nature20805. Epub 2017 Jan 4.

PMID:
28052061
11.

ALK: a tyrosine kinase target for cancer therapy.

Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, Sanchez NS, Zeng J, Shufean MA, Shaw KR, Mendelsohn J, Mills GB, Meric-Bernstam F, Simon GR.

Cold Spring Harb Mol Case Stud. 2017 Jan;3(1):a001115. doi: 10.1101/mcs.a001115. Review.

12.

Role of RPL39 in Metaplastic Breast Cancer.

Dave B, Gonzalez DD, Liu ZB, Li X, Wong H, Granados S, Ezzedine NE, Sieglaff DH, Ensor JE, Miller KD, Radovich M, KarinaEtrovic A, Gross SS, Elemento O, Mills GB, Gilcrease MZ, Chang JC.

J Natl Cancer Inst. 2016 Dec 31;109(6). pii: djw292. doi: 10.1093/jnci/djw292. Print 2017 Jun.

PMID:
28040796
13.

Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling.

Hill SM, Nesser NK, Johnson-Camacho K, Jeffress M, Johnson A, Boniface C, Spencer SE, Lu Y, Heiser LM, Lawrence Y, Pande NT, Korkola JE, Gray JW, Mills GB, Mukherjee S, Spellman PT.

Cell Syst. 2017 Jan 25;4(1):73-83.e10. doi: 10.1016/j.cels.2016.11.013. Epub 2016 Dec 22.

14.

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer.

Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E.

Ann Oncol. 2016 Dec 19. pii: mdw672. doi: 10.1093/annonc/mdw672. [Epub ahead of print]

PMID:
27993796
15.

ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP.

Muranen T, Selfors LM, Hwang J, Gallegos LL, Coloff JL, Thoreen CC, Kang SA, Sabatini DM, Mills GB, Brugge JS.

Cancer Res. 2016 Dec 15;76(24):7168-7180. Epub 2016 Oct 20.

PMID:
27913436
16.

Neomorphic mutations create therapeutic challenges in cancer.

Takiar V, Ip CK, Gao M, Mills GB, Cheung LW.

Oncogene. 2017 Mar 23;36(12):1607-1618. doi: 10.1038/onc.2016.312. Epub 2016 Nov 14. Review.

PMID:
27841866
17.

The rise of genomic profiling in ovarian cancer.

Previs RA, Sood AK, Mills GB, Westin SN.

Expert Rev Mol Diagn. 2016 Dec;16(12):1337-1351.

PMID:
27828713
18.

Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy.

Khotskaya YB, Mills GB, Mills Shaw KR.

Annu Rev Med. 2017 Jan 14;68:113-125. doi: 10.1146/annurev-med-102115-021556. Epub 2016 Nov 2.

PMID:
27813876
19.

Loss-of-function screens of druggable targetome against cancer stem-like cells.

Song M, Lee H, Nam MH, Jeong E, Kim S, Hong Y, Kim N, Yim HY, Yoo YJ, Kim JS, Kim JS, Cho YY, Mills GB, Kim WY, Yoon S.

FASEB J. 2017 Feb;31(2):625-635. doi: 10.1096/fj.201600953. Epub 2016 Oct 20.

20.

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.

Rhyasen GW, Hattersley MM, Yao Y, Dulak A, Wang W, Petteruti P, Dale IL, Boiko S, Cheung T, Zhang J, Wen S, Castriotta L, Lawson D, Collins M, Bao L, Ahdesmaki MJ, Walker G, O'Connor G, Yeh TC, Rabow AA, Dry JR, Reimer C, Lyne P, Mills GB, Fawell SE, Waring MJ, Zinda M, Clark E, Chen H.

Mol Cancer Ther. 2016 Nov;15(11):2563-2574. Epub 2016 Aug 29.

PMID:
27573426

Supplemental Content

Loading ...
Support Center